

Alfredo Berruti  
Oncologia Medica  
Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica  
Università degli Studi di Brescia  
Azienda Ospedaliera Spedali Civili  
Piazzale Spedali Civili, 1  
25123 BRESCIA ( Italy)  
tel [+39 030 3995410](tel:+390303995410)  
email: [alfredo.berruti@gmail.com](mailto:alfredo.berruti@gmail.com)

Date of birth 07/02/1958  
Actual Position  
Full Professor Medical Oncology

## **EDUCATION, AND PROFESSIONAL EXPERIENCE**

1981/1984 Medical Student at the Clinica Medica Università di Torino – Ospedale Molinette Torino,

1985/1989 Post doc yellow at the Patologia Medica Università di Torino – Ospedale San Vito Torino,

1989/1989 Assistant Internal Medicine at the Patologia Medica Università di Torino – Ospedale San Luigi Gonzaga Orbassano (TO),

1999/2006 Senior Assistant Medical Oncology at the Oncologia Medica Università di Torino – Azienda Ospedaliera San Luigi Gonzaga Orbassano (TO).

2006/November 2012: Associate Professor Medical Oncology at the Dipartimento di Scienze Cliniche e Biologiche, Università di Torino. Oncologia Medica – Azienda Ospedaliera San Luigi Gonzaga, Orbassano (TO),

November 2012 onwards: Associate Professor Medical Oncology at the Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia. Chief of the Medical Oncology Unit at the Spedali Civili Hospital in Brescia, Italy

September 2016 onwards, Full Professor Medical Oncology at the Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia. Chief of the Medical Oncology Unit at the Spedali Civili Hospital in Brescia, Italy

## **MAIN RESEARCH FIELDS**

- Pre-clinical, clinical and translational research on endocrine and neuroendocrine malignancies with particular emphasis on adreno cortical malignancies and pheochromocitomas/paragangliomas
- Bone metabolic aspects in patients with bone metastases from various primary malignancies.
- Clinical and translational research in prostate cancer

- Clinical and translational research in breast cancer with particular emphasis on predictive factors for treatment response and tumor biology variation in patients undergoing primary systemic therapy
- Psychological distresses in cancer patients

### **NATIONAL AND INTERNATIONAL SOCIETY MEMBERSHIP**

American Society Clinical Oncology  
 Associazione Italiana Oncologia Medica  
 Società Italiana di Urologia Oncologica  
 Società Italiana di Osteoncologia  
 EORTC (genitourinary group)  
 EORTC (endocrine tumor task force) vice chairman  
 European Society Medical Oncology (ESMO): faculty member

### **NATIONAL AND INTERNATIONAL GUIDELINES**

Subject Editor of ESMO guidelines on Endocrine and Neuroendocrine tumors  
 Co-author of European Endocrinology Guidelines on Adrenocortical Carcinoma  
 Co-author of the Italian guidelines on neuroendocrine tumors and bone metastases by the Italian Association of Medical Oncology (AIOM)

### **PUBLICATIONS**

More than 300 papers, 275 of them on peer reviewed journals. Total IF: >1000

### **EXPERIENCE IN CLINICAL TRIAL**

Italian Study Coordinator of the FIRM-ACT-trial (phase III) in advanced adrenocortical carcinoma (IIT); supported by the German Ministry of Research (BMBF).

Principal investigator of the International Phase II trial: Sorafenib plus paclitaxel metronomic chemotherapy in Adreno-Cortical-Carcinoma patients progressing after 1<sup>st</sup> or 2<sup>nd</sup> line cytotoxic chemotherapy, PAXO trial. Conducted in cooperation with the Institute Gustave Roussy in Paris.

Co-principal investigator of the Randomized Phase II trial: Letrozole plus oral cyclophosphamide plus/minus Sorafenib as primary systemic treatment in post-menopausal, estrogen receptor positive, breast cancer patients. Conducted in cooperation with the Breast Unit of Azienda Ospedaliera, Istituti Ospitalieri of Cremona.


Principal investigator of the Italian phase II trial: Bevacizumab plus long acting octreotide and capecitabine in patients with advanced well differentiated neuroendocrine carcinoma.

Principal investigator in the phase III trial “interruption of androgen deprivation therapy versus maintenance and intermittent docetaxel administration versus continuous schedule in advanced castrate resistant prostate cancer patients eligible to docetaxel therapy”,

Principal Investigator and trial coordinator of the national Phase II study: “Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS trial)”

Principal Investigator and trial coordinator of the national Phase II study: “Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Carcinoma progressing after previous chemotherapy lines.” (CABACC trial).

Principal Investigator and trial coordinator of the national Phase II study: “Assessment of bone response after LHRH-A plus Enzalutamide plus/minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospective, phase II, randomized, multicenter study”.

A handwritten signature in black ink, reading "Alfred Vignati". The signature is written in a cursive style with a large, prominent initial 'A'.

Brescia 27/11/2017